EraGen Biosciences signs licensing agreement with Illumina
Do you know when to trade ILMN ?
ILMN | Quote | Chart | News | PowerRating -- EraGen Biosciences, Inc., a biotechnology company that develops, manufactures and markets molecular reagent products and software, has signed a licensing agreement with Illumina, Inc., a developer of array-based solutions for DNA, RNA and protein analysis. Both the companies are based in the US.
Under the terms of the agreement, EraGen Biosciences will have access to Illumina's BeadXpress platform. EraGen will use this platform for the continued development and commercialization of molecular-based clinical multiplexed assays with its patented MultiCode(R)-PLx technology.
Deal Type Partnership
Sub-Category Licensing Agreement
Deal Status Announced: 2009-11-18
Deal Participants
Partner 1 (Company) Illumina, Inc.
Partner 2 (Company) EraGen Biosciences, Inc.
Deal Rationale
This alliance is part of EraGen's strategy to continue to expand its commercial efforts in the molecular diagnostics market.
For full details on Illumina Inc (ILMN) ILMN. Illumina Inc (ILMN) has Short Term PowerRatings at TradingMarkets. Details on Illumina Inc (ILMN) Short Term PowerRatings is available at This Link.
- Illumina Bullish Moving Average Crossover Alert (ILMN) - 03/19/10
- BiomedReports: News and FDA Updates for Idenix (Nasdaq:IDIX), Illumina (NASDAQ:ILMN), MDRNA (NASDAQ:MRNA) - 03/17/10
- Illumina Announces HumanOmniExpress+ Custom BeadChip - 03/16/10
- Illumina and Glenn Close Announce the First Full Coverage DNA Sequencing of a Named Female - 03/11/10
- BiomedReports: News and FDA Updates for DUSA (NASDAQ:DUSA), Illumina (NASDAQ:ILMN), Insmed (Nasdaq:INSM) - 03/04/10
- More News >>


